Leaky gut biomarkers in casein- and gluten-rich diet fed rat model of autism

Abstract: It is proposed that gluten- and casein-rich diets (GRD and CRD) can synergistically exacerbate dysbiosis as comorbidity in autism by worsening leaky gut that affects the brain through the gut–brain axis. In this study, 35 young male rats were divided into 7 groups, Group 1 serves as control; Group 2, clindamycin (CL)-treated; and Group 3, propionic acid (PPA)-induced rodent model of autism. These three groups were fed standard diet until the end of the experiment. Groups 4–7 are rats treated similarly with CL and PPA, then fed on CRD or GRD until the end of the experiment. Serum zonulin, glutathione (GSH), lipid peroxides, and gut microbial composition were measured in the seven studied groups. Data demonstrate the significant increase in serum zonulin as marker of leaky gut in the CL-treated groups fed on CRD or GRD. Lipid peroxides were significantly higher in the serum of GRD-fed rats compared to CRD-fed or normal diet-fed rats. GSH was much lower in CL-treated groups fed on CRD or GRD compared to PPA-treated rats fed on both diets. Both diets differentially affected the diversity of the gut microbiota. This study demonstrates that CRD and GRD exacerbates leaky gut, according to serum zonulin, which was used as marker for increased gut permeability.

Keywords: autism, leaky gut, zonulin, lipid peroxides, glutathione, gut microbiota

1 Introduction

Globally, about 20% of children and adolescents demonstrate mental, behavioral, and neurodevelopmental disorders and these are the prominent reasons of disability in young individuals [1,2]. The etiology of most intellectual disorders, including neurodevelopmental disorders such as autism spectrum disorders (ASD), is unknown, but genetic influences, biochemical abnormalities, and environmental stressors are contributed in the etiology [3]. The interplay between the brain, leaky gut, and the gut microbiota has become a rapidly growing area of research. Increased leaky gut or intestinal permeability has been examined with regard to emotional, behavioral, and neurodevelopmental disorders such as ASD [4,5].

Children with ASD have been found to display an increased immune reactivity against proteins such as gliadin (a gluten-specific protein) and casein (a protein in dairy products). It was demonstrated that children with ASD have high rates of antibodies against gliadin and casein (i.e., anti-gliadin and anti-casein) [6]. Interestingly they also have antibodies against dipeptidyl peptidase 4 (DPP4) as digestive enzyme which is involved both in digestion and in regulation processes such as immune function, pain perception, intracellular signal transduction coupled to control of cell migration and proliferation [7]. It is very important in the processing of gliadin. It is well known that gliadin is broken down into several peptides among which are gliadinomorphin-7 (GM7) [8] an immune reactive peptide with “opioid activity”, and thus it stimulates opioid receptors in the
body [9]. Further degradation of GM7 is therefore necessary and its cleavage is catalyzed by DPP4 which is not very active in ASD patients [10]. As Vojdani et al. reported, the presence of anti-DPP4 would theoretically diminish the amount of circulating DPP4, with concomitant increase in GM7 and the probability of downstream, opioid-like response [10]. It should be highlighted that casein and other dietary peptides are similarly degraded to intermediary substances with opioid properties (e.g., casomorphin) [11] and together these potentially harmful peptides have been termed “exorphins” [12].

Zonulin is a family of architecturally related peptides that are well-known as physiologic modulator of intestinal tight junctions [13]. Zonulin appears to be the primary modulator that is involved in the regulation of gut–blood and blood–brain barriers permeability that were recently related to the pathology of ASD [14]. Zonulin is also a potential inflammatory marker and contributes to intestinal innate immunity. Increased IP coinciding with inflammation has been described in mental disorders in children [15].

1. Zonulin has been associated with low-grade inflammation and autoimmune diseases, as well as ASD, which might have an autoimmune component [16]. Furthermore, in ASD, higher serum zonulin has been associated with social impairment compared to controls [4,5].

2. It is well known that oxidative stress plays a key role in the early phase of intestinal injury, and it implements as the activating factor for intestinal barrier dysfunction, thus prompting the immune imbalance and inflammation [17]. ASD patients with gastrointestinal (GI)–comorbidity and celiac disease (CD) patients demonstrate oxidative stress which is known to worsen in case of gluten-rich diets (GRD). Much lower glutathione (GSH) and higher lipid peroxides are previously recorded in blood of these patients [18–20].

Propionic acid (PPA) as enteric fatty acid bacterial fermentation metabolite has the ability to induce extensive effects on gut, brain, and behavior. Brain tissue from PPA-treated rats demonstrates numerous neurochemical alterations for instance, neuroinflammation, glutamate excitotoxicity, oxidative stress, GSH depletion, and altered membrane phospholipid consistent with findings in ASD patients. Moreover, PPA has additional bioactive properties on neurotransmitter systems, mitochondrial function, intestinal permeability, and immune response. All these PPA-induced alterations are consistent with the signs and the suggested principal etiological mechanisms of ASD and thus, support the use of PPA in rats as a valid animal model of ASD [21,22]. Most recently, our team tested the application of two interventional treatments, Bifidobacterium probiotic treatment and fecal transplantation as two strategies to treat dysbiosis, and social interaction impairment in oral PPA-administered rats. Both treatments were effective in modulating the overgrowth of gut Clostridium bacteria and social impairment in PPA-rodent model of autism [23].

Additionally, transplanting Clostridium difficile-rich gut microbiota of ASD patients into pregnant mice is sufficient to promote the autism-like behavior in offspring [24]. These findings highlight the contribution of the gut–brain axis in the etiology of autism and recommend possible interventions in a preclinical model of autism.

A fundamental hypothesis proposed that antibiotic treatment kills native intestinal bacterial inhabitants that usually compete with pathogenic bacteria such as C. difficile. It is well known that a single dose of clindamycin (CL) significantly reduces the diversity of the intestinal microbiota for at least 28 days, and induces a remarkable increase in C. difficile as PPA producers. Thus, CL treatment could be used as indirect strategy to test the neurotoxic effect of PPA through the induction of C. difficile overgrowth [25].

This information initiates our interest to measure serum zonulin as marker of impaired gut microbiota together with GSH and lipid peroxides as antioxidant and oxidative stress status markers, respectively, in CL-treated and PPA-induced rodent model of autism fed on standard diet (SD), casein-rich diet (CRD), and GRD. This might help in understanding and ascertain the relationship between casein and gluten sensitivity, oxidative stress, and leaky gut in ASD.

2 Material and methods

2.1 Formulation of CRDs and GRDs

Both CRD and GRD were formulated by Dyets for laboratory animal’s research and all constituents are shown in Tables 1 and 2, respectively.

2.2 Experimental animal model

Total of 35 healthy male rats weighing 80–100 g were obtained from Prince Naif Animal Research Centre and used in all studies. All experimental procedures for evaluating ASD development were performed on 3 week-old animals. The rats were randomly divided into either control or CL-treated and PPA-treated (ASD) groups. Animals
were allowed access to standard rodent chow and tap water ad libitum.

All rats were housed 2 per cage under controlled environmental conditions (22 ± 1°C) and an established light:dark photoperiod (12:12 h; lights on: 07:00). The experimental procedure is illustrated in Figure 1. On the first day of testing, rats were designated to receive either 1 mL of oral saline (control n = 5), or single dose of 30 mg/kg CL (n = 15) or an oral dose of 250 mg/kg PPA (n = 15) dissolved in distilled water for 3 days [26]. Later, the CL- and PPA-treated groups were sub-divided to feed on either SD (n = 5), GRD (n = 5), or CRD (n = 5) for 28 days.

**Ethical approval**: The research related to animals’ use has been complied with all the relevant national regulations and institutional policies for the care and use of animals. All animal study procedures were approved by the Ethics Committee for Animal Care and Use of King Saud University (No. KSU-SE-19-54).

### 2.3 Collection of serum

Blood sample was collected by direct cardiac puncture in a plane tube without anticoagulant. Serum was collected after centrifugation of blood at 1,100 × g for 10 min. The collected serum samples were immediately stored at −80°C until use. ELISA and biochemical assays were performed in the BMS lab at COM, KASU-HS.

#### 2.3.1 Measurement of lipid peroxidation

The extent of lipid peroxidation was determined by measuring the levels of the lipid peroxidation products and thiobarbituric acid (TBA) reactive substances, mainly malondialdehyde. According to the TBA test by Ruiz-Larrea et al. [27], boiling the samples with TBA at a low pH results in the development of a pink chromogen that can be measured at 532 nm.

---

**Figure 1**: Illustration of the experimental design.
2.3.2 Measurement of reduced GSH

Reduced GSH was measured using the GSH assay, carried out using tissue homogenate according to the method of Beutler and Kelly [28].

2.3.3 Measurement of serum zonulin

Serum zonulin in all groups were measured using ELISA kit, a product of MyBioSource. In this assay, the plate has been pre-coated with rat zonulin antibody. Samples are added to different wells, and serum zonulin binds to antibodies coated on the wells. This is followed by the addition of biotinylated rat zonulin antibody which binds to zonulin in the serum sample. Then, Streptavidin-HRP is added and binds to the biotinylated zonulin antibody. After incubation, unbound Streptavidin-HRP is washed away during the washing step. Substrate solution is then added and color develops relative to the amount of serum rat zonulin. The reaction was ended by adding acidic solution and read at 450 nm. 0.1–40 ng/mL, and sensitivity of 0.042 ng/mL.

2.4 Gut microbiota analyses from fecal samples

Fecal samples of all animal groups were collected and stored at −80°C. Each sample was homogenized using a sonicator for 30 s in 0.1 M pH 7.2 PBS (at a 1:10 weight/volume ratio). The solutions were centrifuged at 3000 rpm for 5 min at 4°C. One milliliter of the fecal supernatant was serially diluted in 9 ml of sterile PBS solution 4 times [29]. Bacterial populations were estimated by growth on nutrient agar, MacConkey agar, 5% sheep blood agar, and Mueller–Hinton agar, while yeast populations were enumerated on Sabouraud dextrose agar using 100 µL of sample from each animal separately. All culture media were incubated at 37°C under aerobic conditions for 18–24 h. The experiment was repeated twice. The average number of bacterial/yeast per plate was recorded. Gram staining and biochemical tests were used to identify the bacterial strains [30].

2.5 Statistical analysis

SPSS version 16.0 was used for data analysis; the results were expressed as mean value ± SE. The data were checked for normality using the Shapiro-Wilk test. Not more than one outlier was excluded to achieve normality for some of the measures. Extreme outliers were determined using box plots and removed when they were more than 3× the data’s interquartile range. Serum biochemical assays were done by two-way ANOVA followed by a Tukey’s post hoc analysis for multiple comparisons with differences considered significant at $P \leq 0.05$.

3 Results and discussion

Recent studies suggest potential, but unconfirmed, associations between dietary, metabolic, infective, and GI influences and the behavioral improvements or exacerbations of ASDs. PPA as a metabolic end product of multiple ASD-associated bacteria, such as Desulfovibrio, Clostridia, and Bacteroidetes, is reasonably linked to ASDs and can induce widespread effects on gut, brain, and behavior [23].

The main findings of the present translational study is a trend of an increase ($P = 0.09$) in serum zonulin in PPA-autism model fed on ND, CRD, and GRD compared to control healthy model fed on ND. Significant increase in serum zonulin was recorded in CL-autism model fed on GRD compared either to control healthy model fed on ND ($P \leq 0.0001$), PPA-autism model fed on both CRD and GRD ($P \leq 0.05$), or CL-autism model fed on ND ($P \leq 0.01$). On the other hand, CRD demonstrates significant increase in serum zonulin compared to control healthy and CL-autism model fed on ND.

In an attempt to understand the mechanisms behind the elevation of zonulin as marker of leaky gut in CRD and GRD-fed rats, we can highlight that both casein as the major milk protein and gliadin as wheat gluten-derived protein are hydrolyzed resulting in the release of heptapeptide hβ-casomorphin-7 (hBCM7), bβ-casomorphin-7 (bBCM7), and α-gliadin yields GM7. Different amino acids at positions 3–5 of these proteins together with the presence of 2–3 proline residues give them unique conformations which are resistant to the action of intestinal proteolytic enzymes [31]. Each of these homologous proline-rich peptides has the ability to initiate opioid receptors [32–34].

PPA-treated animals fed on ND, CRD, and GRD might indicate higher permeability with a $P$-value of 0.09, but a higher sample size is recommended to be confident to suggest this. The significant increase in serum zonulin in CRD- and GRD-CL-treated rats compared to CL-treated rats fed on ND could help to suggest that both GRD- and CRD worsen intestinal hyper permeability as realistic
consequences of feeding both diets to CL-treated rats but not in PPA-treated rats. Significant levels of zonulin were observed as marker of intestinal permeability in GRD- and CRD-fed CL-treated rats compared to those fed on ND ($P < 0.001$ and $0.01$, respectively) (Figure 2). This could be related to the opioid-excess hypothesis of autism. It is well documented that children with ASD have shown impaired protein digestion together with intestinal hyperpermeability, and raised levels of urinary peptides of dietary origin classified as exorphins (exogenous opioids) among which are casomorphins, and gliadinomorphins as breakdown products of casein and gluten [35]. Alβ-casein involves both opioid and non-opioid signaling pathways, it increases total GI transit time and colonic myeloperoxidase as opioid receptor-mediated effects, and DPP-4 activity modulation as opioid receptors-independent together with the pro-inflammatory effects [36]. Gliadin as wheat-derived exorphine stimulates the production of pro-inflammatory cytokines for instance interleukin (IL)-1β, tumor necrosis factor-α, IL-6,8,15, and induces the release of zonulin as marker of leaky gut [37–39]. Zonulin activates epidermal growth factor receptor which in turn increases intestinal permeability through the change in tight junction proteins [40,41].

Based on the excess opioid theory, casomorphins and gliadinomorphins agonist of opioid receptors can induce systemic effects and are able to cross the blood–brain barrier [35]. Treatment of these ASD subjects with an extended gluten-free, casein-free diet for 2–4 years resulted in significant decrease in urinary peptide levels as well as satisfactory improvement in the autistic behavioral measures [35,42,43], regardless of abundant intake of meat and fish protein, which can help to relate CRD and GRD to excess opioid theory [35]. More support can be found in considering multiple animal studies which demonstrated that inhibition of gut peptidases, specifically DPP-4, results in increased levels of urinary peptides of dietary origin [10,43,44].

Both lipid peroxidation and GSH was unaffected in the serum of PPA- and CL-treated rats fed on ND (Figures 3 and 4). This is in contrast to the effects of both treatments on brain tissues of treated animals which demonstrate increase in lipid peroxides and GSH depletion as oxidative stress markers [26,45]. This could be explained on the
basis that rat brain is especially susceptible to oxidative stress as neurotoxic effects of PPA and CL [46,47].

Lipid peroxides were significantly higher in PPA-treated rats fed on GRD compared to those fed on ND or even CRD. Similarly, increase was observed in GRD fed rats treated with CL in comparison to those on ND. This is in good agreement with numerous studies which emphasized the immunologic or molecular mechanisms of gluten toxicity, specifically demonstrating that gliadin as proline-rich peptide shows an important role in exerting cytotoxic and immunomodulatory activities, as well as triggering oxidative stress in patients with GI morbidity such as celiac disease (CD) patients [48–50]. It is very interesting to note that enzymatically prepared wheat gluten hydrolysate (WGH) had antioxidant effects [51,52]. The contrasting effects seen between gluten/gliadin and WGH ascertain the contribution of the incomplete digestion of gluten and its toxic effect through gliadin.

Table 1: Ingredients of CRD

| Ingredient                  | kcal/g | g/kg | kcal/kg |
|----------------------------|--------|------|--------|
| Casein, high nitrogen      | 3.58   | 200  | 716    |
| L-Cystine                  | 4      | 3    | 12     |
| Sucrose                    | 4      | 100  | 400    |
| Cornstarch                 | 3.6    | 342.786 | 1234.0296 |
| Dextrose                   | 3.8    | 132  | 501.6  |
| Soybean oil               | 9      | 70   | 630    |
| L-Butyhydroquinone         | 0      | 0.014| 0      |
| Cellulose                  | 0      | 50   | 0      |
| Mineral mix #210025        | 0.88   | 35   | 30.8   |
| Vitamin mix #310025        | 3.87   | 10   | 38.7   |
| Choline bitartrate         | 0      | 2.5  | 0      |
| Total                      | 1,000  | 3760.0496 |       |

Table 2: Ingredients of GRD

| Ingredient                  | kcal/g | g/kg | kcal/kg |
|----------------------------|--------|------|--------|
| Wheat gluten               | 3.68   | 200  | 920    |
| Sucrose                    | 4      | 100  | 400    |
| Cornstarch                 | 3.6    | 342.786 | 1234.0296 |
| Dextrose                   | 3.8    | 132  | 501.6  |
| Soybean oil               | 9      | 70   | 630    |
| L-Butyhydroquinone         | 0      | 0.014| 0      |
| Cellulose                  | 0      | 50   | 0      |
| Mineral mix #210025        | 0.88   | 35   | 30.8   |
| Vitamin mix #310025        | 3.87   | 10   | 38.7   |
| Choline bitartrate         | 0      | 2.5  | 0      |
| L-Methionine               | 4      | 3    | 12.00  |
| L-Lysine                   | 4      | 3.7  | 14.80  |
| L-Threonine                | 4      | 4.00 | 0      |
| Total                      | 1000.00 | 3785.9296 |        |

Table 3: Approximate microorganism colony count/plate in all treatment groups

| Isolated organisms                  | Group 1 control | Group 2 CL-ND | Group 3 CL-CRD | Group 4 PPA | Group 5 PPA-ND | Group 6 PPA-CRD | Group 7 PPA-GRD |
|-------------------------------------|-----------------|---------------|----------------|-------------|----------------|-----------------|----------------|
| Staphylococcus and/or bacilli (gram-positive cocci) / rods or gram-negative rods (fermenters) | MA, aerobic: 37°C, 24 h | +++  | +++ | +++ | +++ | +++ | +++ |
| Enterobacteraceae (gram-negative rods and cocci) | MCA, aerobic: 37°C, 24 h | +  | +  | +  | +  | +  | +  |
| Gram-positive/gram-negative rods and cocci | BAP, anaerobic: 37°C, 24 h | ++ | ++ | ++ | ++ | ++ | ++ |
| Moraxella spp. | MHA, aerobic: 37°C, 24 h | +  | +  | +  | +  | +  | +  |
| Candida albicans | SDA, aerobic: 25°C, 48 h | +  | +  | +  | +  | +  | +  |

= no growth; ++ = rare; +++ = few; +++ = moderate; ++++ = heavy; MA, nutrient agar; MCA, MacConkey agar; BAP, 5% sheep blood agar; MHA, Mueller-Hinton agar; SDA, sabouraud dextrose agar (yeast media).
The GI tract has been related to autism through the gut–brain axis. Several reports demonstrate the over-representation of functional and pathological gut conditions in individuals with autism [53,54], the influence of different dietary interventions for autism [55], and the novel triad involving GI immune function–intestinal barrier permeability–gut microbiota [56] potentially being relevant to some of the autistic features in humans and rodent models. Recently in 2020, Forsyth [57] reported the decrease in the abundance of certain bacteria among which is Moraxella in ASD individuals compared to typically developing children. Table 3 demonstrates the remarkable decrease in Moraxella in CL-treated rats fed on ND as rodent model of autism (Group 2), absence in CL-treated rats fed on GRD, PPA-treated rats fed on CRD or GRD (Groups 4, 6, and 7), and a remarkable increase in CL-treated rats fed on CRD. This can find support in the recent work of Forsyth et al. [58] in which he recorded 31.9% lower abundance of Moraxella in individuals with ASD compared to healthy controls. Moraxella has a tendency to secrete multiple hydrolytic enzymes among which are proteases which catalyze the hydrolysis of casein that might be related to the production of casomorphins as exorphins [59].

Moreover, the recorded growth of Candida albicans in PPA-treated GRD-fed rats could be supported by the work of Harnett et al. [60] which detects Candida sp. in 33% of CD fecal specimens as disease related to gluten sensitivity compared to 0% of the control group confirming the idea that Candida may act as a trigger of autoimmune responses in genetically predisposed subjects. Thus, Candida components might theoretically contribute to CD etiology by modifying immunogenic epitopes of gluten and resulting in immune response. The reported growth of C. albicans in PPA-treated rats fed on GRD could be explained on the basis that Candida is well-adapted for growth in the gut where inflammation may disturb the inhabitant bacterial community generating conditions that favor Candida growth and inflammation. The recorded growth of Candida in PPA group fed on GRD (Table 3) could be explained through considering the opioid-excess hypothesis of autism and the ability of gliadin to initiate opioid receptors. It was shown that morphine as opioid analgesics reduced the phagocytic and fungicidal activity of macrophages towards C. albicans, which could explain the noticed growth in response to GRD [61,62]. The absence of C. albicans growth in CL-treated group fed on GRD (Group 7) could be explained through considering the early study of Kennedy and Volz [63]. It was found that CL reduced anaerobic population levels, but not enteric bacilli or aerobes, also animals prone to mucosal association by C. albicans. It is suggested that the strictly anaerobic bacterial populations which predominate in the gut in CL-treated rats (Enterobacteriaceae) are responsible for the inhibition of C. albicans adhesion, colonization, and diffusion from the intestinal tract (Table 3; Groups 2, 3, and 4). This explanation could be further supported through considering the most recent work of Markey et al. [64], who reported that bacterial colonization and the C. albicans are more easily changed by CL treatment providing perception into the microbiota response to acute CL challenge and the effect of C. albicans colonization on ecological resistance.

4 Conclusion

In conclusion, CRD and GRD can deteriorate intestinal permeability leading to higher levels of serum zonulin as marker of leaky gut. Moreover, both diets have synergistic effects on dysbiosis as a contributing factor in the development of GI comorbidity in ASD. Thus, dietary and microbial interventions to promote a healthy microbial profile in ASD patient could be suggested.

Acknowledgements: This research project was supported by a grant from the Researchers Supporting Project number (RSP-2021/341), King Saud University, Riyadh, Saudi Arabia.

Author contributions: conceptualization, A.E. and H.A.A.; methodology, H.A.D and R.S. B.; software, S.A.; validation, A.E., H.A.D., and B.A.; formal analysis, S.A. and B.A.; investigation, R.S.B., D.A., and M.A.; resources, M.A.; data curation, H.A.D. and B.A.; writing – original draft preparation, A.E.; writing – review and editing, H.A.D.; visualization, H.A.A.; supervision, A.E. and H.A.A.; project administration, H.A.A.; funding acquisition, M.A.

Conflict of interest: Authors state no conflict of interest.

Data availability statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Hansen BH, Oerbeck B, Skirbekk B, Petrovski BÉ, Kristensen H. Neurodevelopmental disorders: prevalence and comorbidity in children referred to mental health services. Nord J Psychiatry. 2018;72:285–91. doi: 10.1080/08039488.2018.1444087.
[2] Stein DJ, Szatmari P, Gaebel W, Berk M, Vieta E, Maj M, et al. Mental, behavioral and neurodevelopmental disorders in the ICD-11: an international perspective on key changes and controversies. BMC Med. 2020;18:21. doi: 10.1186/s12916-020-1495-2.

[3] Cheroni C, Caporale N, Testa G. Autism spectrum disorder at the crossroad between genes and environment: contributions, convergences, and interactions in ASD developmental pathophysiology. Molecular Autism. 2020;11:69. doi: 10.1186/s13229-020-00370-1.

[4] Sharon G, Cruz NJ, Kang DW, Gandal MJ, Wang B, Kim YM, et al. Human gut microbiota from autism spectrum disorder promote behavioral symptoms in mice. Cell. 2019;177(6):1600–18.e17. doi: 10.1016/j.cell.2019.05.004.

[5] Esnafigli E, Cirrik S, Ayyildiz SN, Erdil A, Ertürk EY, Daglı A, et al. Emerging roles for the gut microbiome in autism spectrum disorder. Biol Psychiatry. 2017 Mar 1;81(5):411–23. doi: 10.1016/j.biopsych.2016.08.024. Epub 2016 Aug 26. PMID: 27773355; PMCID: PMC5285286.

[6] de Magistris L, Picardi A, Siniscalco D, Riccio MP, Sapone A, Cariello R, et al. Antibodies against food antigens in patients with autistic spectrum disorders. Biomed Res Int. 2013;2013:729349. doi: 10.1155/2013/729349.

[7] Kahne T, Lendeckel U, Wrenger S, Neubert K, Ansorge S, Reinhold D. Dipeptidyl peptidase IV: a cell surface peptidase involved in regulating T cell growth (review). Int J Mol Med. 1999;4:3–15.

[8] Pruimboom L, de Punter K. The opioid effects of gluten exorphins: asymptomatic celiac disease. J Health Popul Nutr. 2015;33:24. doi: 10.1186/s40103-015-0032-y.

[9] Trivedi MS, Shah JS, Al-Mughairi S, Hodgson NW, Simms B, Trooskens GA, et al. Food-derived opioid peptides inhibit cysteine uptake with redox and epigenetic consequences. J Nutr Biochem. 2014;25:1011–8. doi: 10.1016/j.jnutbio.2014.05.004.

[10] Vojdani A, Bazargan M, Vojdani E, Samadi J, Nourian AA, Eghbali N, et al. Heat shock protein and gliadin peptide development of peptidase antibodies in children with autism and patients with autoimmune disease. Clin Diag Immunol. 2004 May;11(3):515–24. doi: 10.1128/CDI.11.3.515-524.2004. PMID: 15381767; PMCID: PMC4046567.

[11] Nguyen DD, Johnson SK, Busetti F, Solah VA. Formation and degradation of beta-casomorphins in dairy processing. Crit Rev Food Sci Nutr. 2015;55:1955–67. doi: 10.1080/10408398.2012.740102.

[12] Dohan FC. Genetic hypothesis of idiopathic schizophrenia: its exorphin connection. Schizophr Bull. 1988;14:489–94. doi: 10.1093/schbul/14.4.489.

[13] Sturgeon C, Lan J, Fasano A. Zonulin transgenic mice show altered gut permeability and increased morbidity/mortality in the DSS colitis model. Ann N Y Acad Sci. 2017;1397:130–42. doi: 10.1111/nyas.13343.

[14] Asbjørnsdottir B, Snorradottir H, Andresdottir E, Fasano A, Lauth B, Gudmundsson LS, et al. Zonulin-dependent intestinal permeability in children diagnosed with mental disorders: a systematic review and meta-analysis. Nutrients. 2020;12(7):1982. doi: 10.3390/nu12071982.

[15] Hensley-McBain T, Manuzak JA. Zonulin as a biomarker and potential therapeutic target in multisystem inflammatory syndrome in children. J Clin Invest. 2021;131(14):e151467. doi: 10.1172/JCI151467.

[16] Fasano A, Zoulin and its regulation of intestinal barrier function: the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011;91:151–75. doi: 10.1152/physrev.00003.2008.

[17] Tian T, Wang Z, Zhang J. Pathomechanisms of oxidative stress in inflammatory bowel disease and potential antioxidant therapies. Oxid Med Cell Longev. 2017;2017:4535194. doi: 10.1155/2017/4535194.

[18] Nadeem A, Ahmad SF, Al-Harbi NO, Attia SM, Alshammari MA, Al-Zahrani KS, et al. Increased oxidative stress in the cerebellum and peripheral immune cells leads to exaggerated autism-like repetitive behavior due to deficiency of antioxidant response in BTBR T +tf/ mice. Prog Neuro-Psychoarmacol Biol Psychiatry. 2018;89:245–53. doi: 10.1016/j.pnpbp.2018.09.012.

[19] Pangrazzi L, Balascco L, Bozzi Y. Oxidative stress and immune system dysfunction in autism spectrum disorders. Int J Mol Sci. 2020;21(9):3293. doi: 10.3390/ijms21093293. PMID: 32844730; PMCID: PMC7247582.

[20] Al-Yafee YA, Al-Ayadhi LY, Haq SH, El-Ansary AK. Novel metabolic biomarkers related to sulfur-dependent detoxification pathways in autistic patients of Saudi Arabia. BMC Neurol. 2011 Nov 4;11:139. doi: 10.1186/1471-2377-11-139. PMID: 22051046; PMCID: PMC3217885.

[21] James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B Neuropsychiatr Genet. 2006 Dec 5;141B(8):947–56. doi: 10.1002/ajmg.b.30366. PMID: 16919739; PMCID: PMC2610366.

[22] Shultz SR, MacFabe DF. Propionic acid animal model of autism. In: Patel V, Preedy V, Martin C, editors. Comprehensive guide to Autism. New York, NY: Springer; 2014. doi: 10.1007/978-1-4614-4788-7_106.

[23] Abuaiash S, Al-Otaibi NM, Abujamel TS, Alzahrani SA, Alotaibi SM, AlShawakir YA, et al. Fecal transplant and bifidobacterium treatments modulate gut clostridium bacteria and rescue social impairment and hippocampal bdnf expression in a rodent model of autism. Brain Sci. 2021;11:1038. doi: 10.3390/brainsci11081038.

[24] Al-Gadani Y, El-Ansary A, Attas O, Al-Ayadhi L. Metabolic biomarkers related to oxidative stress and antioxidant status in Saudi autistic children. Clin Biochem. 2009 Jul;42(10–11):1032–40. doi: 10.1016/j.clinbioch.2009.03.011. Epub 2009 Mar 21. PMID: 19306862.

[25] Buffie CG, Lucke M, Martin E, Lepure D, Loubiere C, Borel B, et al. Profound alterations of intestinal microbiota following a single dose of clindamycin result in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun. 2012;80(1):62–73. doi: 10.1128/IAI.05496-11.

[26] El-Ansary AK, Bacha AB, Kom M. Etiology of autistic features: the persisting neurotoxic effects of propionic acid. J Neuroinflamm. 2012;9(1):74.

[27] Ruiz-Larrea MB, Leal AM, Liza M, Lacort M, de Groot H. Antioxidant effects of estradiol and 2-hydroxyestradiol on iron-induced lipid peroxidation of rat liver microsomes. Steroids. 1994;59(6):383–8.
Kami Tripathi A, Lammers KM, Goldblum S, Shea Reichelt KL, Knivsberg AM. Can the pathophysiology of autism de Punder K, Pruimboom L. The dietary intake of wheat and Koch G, Wiedemann K, Teschemacher H. Opioid activities of Vincentini O, Maialetti F, Gonnelli E, Silano M. Gliadin Huβner FR, Lieberman KW, Rubino RP, Wall JS. Demonstration of high opioid-like activity in isolated peptides from wheat gliuten hydrolysates. Peptides. 1984;5(6):1139–47. PubMed: 6099562.

Reichelt KL, Knivsberg AM. Can the pathophysiology of autism be explained by the nature of the discovered urine peptides? Nutr Neurosci. 2003;6:19–28. doi: 10.1080/10284502000042839.

Barnett MP, McNabb WC, Roy NC, Woodford KB, Clarke AJ. Dietary A1 β-casein affects gastrointestinal transit time, dipeptidyl peptidase-4 activity, and inflammatory status relative to A2 β-casein in Wistar rats. Int J Food Sci Nutr. 2014;65(6):720–7.

de Punder K, Pruimboom L. The dietary intake of wheat and other cereal grains and their role in inflammation. Nutrients. 2013;5(3):771–87.

Gujral N, Suh JW, Sunwoo HH. Effect of anti-gliadin IgY antibody on epithelial intestinal integrity and inflammatory response induced by gliadin. BMC Immunol. 2015;16:41.

Vincentini O, Maialletti F, Gonnelli E, Silano M. Gliadin-dependent cytokine production in a bidimensional cellular model of celiac intestinal mucosa. Clin Exp Med. 2015;15(4):447–54.

Lammers KM, Lu R, Brownley J, Lu B, Gerard C, Thomas K, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008;135(1):194–204.e3.

Tripathi A, Lammers KM, Goldblum S, Shea-Donohue T, Netzelt-Arnett S, Buzza MS, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA. 2009;106(39):16799–804.

Reichelt KL, Knivsberg AM. The possibility and probability of a gut-to-brain connection in autism. Ann Clin Psychiatry. 2009;21:205–11.

Reichelt KL, Tveiten D, Knivsberg AM, Bronstad G. Peptides’ role in autism with emphasis on exorphins. Microb Ecol Health Dis. 2012;23:18958. doi: 10.3402/mech.v23i0.18958.

Mahe S, Tome D, Dumontier AM, Desjeux JF. Absorption of intact morphicentin by disopropylfluorophosphate-treated rabbit ileum. Peptides. 1989;10:45–52. doi: 10.1016/0196-9781(89)90074-0.

Watanabe Y, Kojima-Komatsu T, Iwaki-Egawa S, Fujimoto Y. Increased excretion of proline-containing peptides in dipeptidyl peptidase IV-deficient rats. Res Commun Chem Pathol Pharmacol. 1993;81:323–30.

MacFabe DF, Cain DP, Rodriguez-Capote K, Franklin AE, Hoffman JE, Boon F, et al. Neurobiological effects of intravenous propionic acid in rats: possible role of short chain fatty acids on the pathogenesis and characteristics of autism spectrum disorders. Behavioural Brain Res. 2007;176(1):149–69.

Wang X, Michaelis EK. Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci. 2010;30(2):12. doi: 10.3389/fnagi.2010.00012.

Cobleyn JN, Fiorello ML, Bailey DM. 13 reasons why the brain is susceptible to oxidative stress. Redox Biol. 2018;15:490–503. doi: 10.1016/j.redox.2018.01.008.

Leonard MM, Sapone A, Catassi C, Fasano A. Celiac disease and nonceliac gluten sensitivity. J Am Med Assoc. 2017;318:647–56.

Ferretti G, Bacchetti T, Masciangelo S, Saturni L. Celiac disease, inflammation and oxidative damage: a nutrigenetic approach. Nutrients. 2012;4:243–57.

Kumar J, Kumar M, Pandey R, Chauhan NS. Physiopathology and management of gluten-induced celiac disease. J Food Sci. 2017;82:270–7.

Horiguchi N, Horiguchi H, Suzuki Y. Effect of wheat gluten hydrolysate on the immune system in healthy human subject. Biosci Biotechnol Biochem. 2005;69:2445–9.

Park EY, Imazu H, Matsumura Y, Nakamura Y, Sato K. Effects of peptide fractions with different isoelectric points from wheat gluten hydrolysates on lipid oxidation in pork meat patties. J Agric Food Chem. 2012;60:7483–8.

McElhanon BO, McCracken C, Karpen S, Sharp WG. Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis. Pediatrics. 2014;133:872–83.

Doshi-Velez F, Avillach P, Palmer N, Bousvaros A, Ge Y, Fox K, et al. Prevalence of inflammatory bowel disease among patients with autism spectrum disorders. Inflamm Bowel Dis. 2015;21:2281–8.

Whiteley P, Shattock P, Knivsberg AM, Seim A, Reichelt KL, Todd L, et al. Gluten- and casein-free dietary intervention for autism spectrum conditions. Front Hum Neurosci. 2013;6:344.

Forsyth A. Children with autism spectrum disorder: pilot studies examining the salivary microbiome and implications for gut metabolism and social behavior. Human Microbiome J. 2020;15:100066.

Forsyth A, Raslan K, Lyashenko C, Bousa S, Snow ML, Hkor B, et al. Children with autism spectrum disorder: pilot studies examining the salivary microbiome and implications for gut metabolism and social behavior. Human Microbiome J. 2019;15:100066. doi: 10.1016/j.jhumic.2019.100066.

Frank SK, Gerber JD. Hydrolytic enzymes of Moraxella bovis. J Clin Microbiol. 1981 Feb;13(1):269–71.

Harnett J, Myers SP, Rolfe M. Significantly higher faecal counts of the yeasts Candida and saccharomyces identified in people with celiac disease. Gut Pathog. 2017;9:26. doi: 10.1186/s13099-017-0173-1.

Tubor E, Ávico U, Santiangeli C, Zuccaro P, Cavallo G, Pacifi R, et al. Morphine and methadone impact on human
phagocytic physiology. Int J Immunopharmacol. 1985;7:865–74. doi: 10.1016/0192-0561(85)90049-9.

[62] Rojavin M, Szabo I, Bussiere JL, Rogers TJ, Adler MW, Eisenstein TK. Morphine treatment in vitro or in vivo decreases phagocytic functions of murine macrophages. Life Sci. 1993;53:997–1006. doi: 10.1016/0024-3205(93)90122-J.

[63] Kennedy MJ, Volz PA. Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia. 1985;23(4):265–73. doi: 10.1080/00362178585380391.

[64] Markey L, Pugliese A, Tian T, Roy F, Lee K, Kumamoto CA. Decreased ecological resistance of the gut microbiota in response to clindamycin challenge in mice colonized with the fungus Candida albicans. mSphere. 2021;6:e00982-20. doi: 10.1128/mSphere.00982-20.